CAR T-cell therapy is currently approved to treat six types of blood cancer. All seven FDA-approved products target cancers of the blood and immune system, not solid tumors. The therapy works by reprogramming a patient’s own immune cells to recognize and destroy cancer, and for certain blood cancers that haven’t responded to other treatments, it can produce complete remission in a significant number of patients.
Blood Cancers With FDA-Approved Treatments
Every CAR T-cell product on the market targets a blood cancer. The FDA has approved seven products across six cancer types:
- B-cell acute lymphoblastic leukemia (ALL), the most common childhood cancer and a fast-growing leukemia in adults. This was the first cancer treated with CAR T-cell therapy.
- Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in adults.
- Follicular lymphoma, a slower-growing form of non-Hodgkin lymphoma.
- Mantle cell lymphoma, a rarer and often aggressive non-Hodgkin lymphoma.
- Multiple myeloma, a cancer of plasma cells in the bone marrow.
- Primary mediastinal large B-cell lymphoma, a subtype that typically develops in the chest.
These cancers share a common trait: the cancer cells display specific proteins on their surface that CAR T-cells can be engineered to find. Most approved therapies target a protein called CD19, which sits on the surface of B cells (a type of white blood cell). The two products approved for multiple myeloma target a different protein called BCMA, found on plasma cells.
How Well It Works for Each Cancer
The results vary by cancer type, but the numbers are striking for patients who’ve run out of other options. In B-cell ALL, a meta-analysis across clinical trials found a complete remission rate of 81%, with 81% of those patients also showing no detectable residual disease at four weeks. The estimated median overall survival was 15 months, and about 57% of patients were alive at one year. These are patients whose cancer had already resisted or relapsed after standard chemotherapy.
For multiple myeloma, two approved products have shown meaningful but different results. In the pivotal trial for the first approved product, median progression-free survival was 8.8 months and median overall survival was 19.4 months. The second product performed better in its trial: at 27 months, about 55% of patients hadn’t seen their cancer progress and 70% were still alive. Again, these were patients who had already tried multiple prior treatments.
For DLBCL and other large B-cell lymphomas, roughly 30 to 40% of patients treated with CAR T-cell therapy achieve durable long-term remissions, meaning the cancer hasn’t returned years later. That’s a meaningful number for a group of patients who previously had very few options.
No Approved Treatments for Solid Tumors Yet
CAR T-cell therapy does not currently treat any solid tumor, including breast, lung, colon, or prostate cancer. This is the biggest limitation of the technology right now. Solid tumors create barriers that blood cancers don’t: they build a physical microenvironment that suppresses immune cells, they lack the clean surface targets that blood cancers have, and the CAR T-cells struggle to penetrate deep into tumor tissue.
That said, early-phase clinical trials are underway for several solid cancers. Glioblastoma (an aggressive brain cancer) has multiple Phase I trials testing different CAR T-cell designs, including cells engineered to target two proteins simultaneously. Small cell lung cancer and large cell neuroendocrine carcinoma have a Phase I trial testing a product that targets a protein called DLL3. Pancreatic cancer, ovarian cancer, and non-small cell lung cancer are being studied in a Phase I/II trial using a newer “logic-gated” CAR T-cell designed to reduce damage to healthy tissue. All of these remain experimental, with no timeline for approval.
How CAR T-Cell Therapy Works
The process starts with drawing blood from you through a procedure called leukapheresis, which filters out white blood cells and returns the rest of your blood. Your T-cells (immune cells that normally fight infections) are then isolated and sent to a manufacturing facility. There, scientists use a modified virus to insert new genetic instructions into your T-cells. These instructions tell the cells to build a synthetic receptor on their surface, the chimeric antigen receptor, or CAR.
This receptor works like a lock-and-key system. The outer portion is designed to recognize a specific protein on cancer cells. When the CAR locks onto that protein, the inner portion of the receptor triggers the T-cell to activate, multiply, and kill the cancer cell. Unlike your natural immune cells, CAR T-cells don’t need the cancer to “present” itself through normal immune channels. They recognize the target protein directly, which makes them effective even against cancers that have learned to hide from the immune system.
Once enough CAR T-cells have been grown in the lab, they’re shipped back and infused into your bloodstream. The entire process from blood draw to infusion typically takes three to five weeks, though the manufacturing step itself is one to two weeks. Before infusion, you’ll receive a short course of chemotherapy to make room in your immune system for the new cells.
Who Is Eligible
CAR T-cell therapy is not a first-line treatment. For most approved uses, you need to have already tried and failed at least two prior lines of therapy, or your cancer must have relapsed after a stem cell transplant. It’s designed for patients whose cancer keeps coming back or never responded to standard treatment in the first place.
Beyond the cancer diagnosis itself, doctors evaluate your overall fitness before recommending CAR T-cell therapy. They look for patients with a manageable tumor burden, normal markers of inflammation, and adequate organ function, particularly heart, kidney, and liver. Your T-cell health matters too, since the therapy depends on your own immune cells being functional enough to engineer. Patients who are rapidly declining or have very aggressive, fast-growing disease at the time of evaluation may not be ideal candidates because the manufacturing process takes weeks.
Side Effects to Know About
The two signature side effects of CAR T-cell therapy are cytokine release syndrome (CRS) and a neurological side effect called immune effector cell-associated neurotoxicity syndrome, or ICANS. Both happen because the treatment triggers an intense immune response.
CRS typically starts within the first few days after infusion. Your activated T-cells release a flood of signaling molecules called cytokines, which can cause high fevers, low blood pressure, difficulty breathing, and fatigue. Most cases are mild to moderate and resolve with supportive care or a medication that blocks the inflammatory cascade. Severe CRS requires intensive monitoring but is manageable when caught early, which is why patients stay near the treatment center for at least two to four weeks after infusion.
ICANS affects the nervous system and can cause confusion, difficulty finding words, tremors, or in severe cases, seizures. A meta-analysis of clinical trials found that about 27% of patients develop some degree of ICANS, and roughly 10.5% experience the severe form. The risk varies substantially depending on the specific product: one commonly used product showed all-grade ICANS in 54% of patients, while another product with a different design saw rates of about 17%. Both CRS and ICANS are usually temporary, resolving within days to a couple of weeks, though some patients experience lingering effects.
Other common side effects include prolonged low blood cell counts, which increase infection risk, and a lasting reduction in healthy B-cells (since the therapy also destroys normal B-cells that carry the same target protein). Patients often need regular infusions of antibodies for months or longer to compensate for this immune gap.